Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Power wheelchair fraud rolled back

This article was originally published in The Gray Sheet

Executive Summary

Unpaid Medicare claim rate is 98.4% for power wheelchairs in Harris County, Texas over the past year, wheelchair distributor The Scooter Store says. CMS' anti-fraud campaign, "Operation Wheeler Dealer," launched in September 2003, singled out Harris County as an area where potential billing fraud appeared "most egregious" and required CMS staff to personally signoff on payments for claims in the region (1"The Gray Sheet" Sept. 15, 2003, p. 4). Medicare paid for more than 31,000 power chairs in 2002 in Harris County, over 10 times the 2001 total of 3,000. TSS charges that the "sharply restrictive" claims review process for Harris represents "geographical discrimination." The firm notes a 95% approval rate for its Medicare power wheelchair claims nationwide...

You may also be interested in...

Power Wheelchairs Targeted For Inherent Reasonableness Price Adjustments

CMS plans to develop inherent reasonableness review guidelines to ensure appropriate Medicare payments for motorized wheelchairs as part of a larger initiative to curb provider billing fraud, the agency says

Sarepta Scores Another Remarkable Approval With Vyondys 53 For Duchenne

Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.

Real-World Evidence Fails Another Test At US FDA

Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts